Quantcast

Latest Zidovudine Stories

2014-04-01 16:25:28

Elizabeth Glaser Pediatric AIDS Foundation Applauds Agreement between the Medicines Patent Pool and ViiV Healthcare WASHINGTON, April 1, 2014 /PRNewswire-USNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare to increase access to dolutegravir (DTG), a promising new antiretroviral (ARV) medication. This agreement will allow generic manufacturers to scale up production of...

2014-04-01 16:25:22

GENEVA, April 1, 2014 /PRNewswire/ -- Access to dolutegravir could improve millions of lives in developing countries The Medicines Patent Pool (MPP) and ViiV Healthcare announced a new collaboration on HIV medicines today, signing two licensing agreements to increase access to dolutegravir (DTG), a promising new antiretroviral, for both adult and paediatric care. The agreements would allow generic...

2014-04-01 16:25:15

- Timely collaborations underscore ViiV Healthcare's commitment to increase access to life-saving HIV medicines for children and adults in the developing world LONDON, April 1, 2014 /PRNewswire/ -- ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name Tivicay®), just two months after its approval by the European Medicines Agency (EMA) and eight months after approval by the US Food and Drug...

2014-03-06 12:28:29

Company Outlines Future Plans for HIV "Functional Cure" RICHMOND, Calif., March 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2014). The conference is being held in Boston from March 3 to 6, 2014. Data from an earlier Phase 1 clinical study in this program were also published in the March 6,...

2014-03-04 13:25:34

A series of papers in the March issue of Health Affairs examines how the Affordable Care Act could affect two sectors of the most vulnerable Americans — those living with HIV/AIDS and people who have recently cycled through jail. The issue features several studies by researchers with the USC Schaeffer Center for Health Policy and Economics, one of the nation's premier policy research centers dedicated to promoting health and value in healthcare delivery through innovative research and...

2014-02-19 11:04:05

Pittsburgh researchers show how therapy-induced resistance to 'NNRTI' drugs works at 58th Annual Biophysical Society Meeting in San Francisco For the more than one million people with HIV/AIDS in the United States (and the over 34 million people living with HIV/AIDS around the world), antiretroviral drugs such as efavirenz and other so-called non-nucleoside reverse transcriptase inhibitors (NNRTIs) in combination with other antiretrovirals can be a lifeline, because they slow the progress...

2014-02-04 11:29:24

Nearly half of HIV-infected teenagers and young adults forego timely treatment, delaying care until their disease has advanced, which puts them at risk for dangerous infections and long-term complications, according to a study led by the Johns Hopkins Children's Center. The researchers say their findings, published Feb. 3 in JAMA Pediatrics, are particularly troubling in light of mounting evidence that starting treatment as early as possible can go long way toward keeping the virus in...

2014-01-31 00:21:48

PITTSBURGH and MUMBAI, India, Jan. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (Nasdaq: GILD) exclusive branded medicines business partner for India. Under the agreement, Mylan will market and distribute in India Gilead's: -- HIV therapies Viread(® )(tenofovir disoproxil fumarate), Truvada(®) (emtricitabine/tenofovir disoproxil fumarate) and the...

2014-01-28 12:20:14

Drugs used to treat HIV penetrate poorly into lymphatic tissues where most HIV replication takes place and there is persistent low-level virus replication in these tissues according to research from the University of Minnesota and University of Nebraska Medical Center. The results appear in the latest issue of the Proceedings of the National Academy of Sciences (PNAS). "We know the drugs we use today are effective because our patients are doing better and living longer, but these drugs...

Researchers Demonstrate 'Guided Missile' Strategy To Kill Hidden HIV
2014-01-10 13:59:06

University of North Carolina Health Care The finding provides a new route to killing persistent HIV-infected cells -- a major roadblock to a cure Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV – a combination therapy that targets HIV-infected cells that standard therapies cannot kill. Using mouse models that have immune systems composed of human cells, researchers led by J. Victor Garcia, PhD, found that an antibody combined with a...


Latest Zidovudine Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »
Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related